However, an earlier study by the World Health Organization showed that Remdesivir had little effect on the treatment of hospitalized patients with new coronary pneumonia.
Five months after the emergency use authorization was approved, the Redsive official announced his conversion.
On the 22nd local time, Gilead Sciences issued an announcement on its official website that the U.S. Food and Drug Administration (FDA) approved Remdesivir for the treatment of patients with new coronary pneumonia. The antiviral drug Remdesivir has become the only approved drug for the treatment of new coronary pneumonia in the world.
Affected by this news, Gilead Science surged over 7% after the market on Thursday.
Gilead Sciences stated in the announcement that Remdesivir can shorten the hospital stay of patients with new coronary pneumonia to 5 days. The drug can only be used in hospitals or medical institutions that provide the same care services as hospitals. Remdesivir cannot be administered in the form of tablets, only by intravenous injection.
Public information shows that Remdesivir is a broad-spectrum antiviral drug under development. It has proved its activity against MERS and SARS virus pathogens in in vitro and in vivo animal models, both of which are also coronaviruses. The above is similar to 2019-nCoV.
Recently, with the announcement of a number of research results, the efficacy of Redecivir in patients with new coronary pneumonia is not uniform.
A little earlier, US President Trump was diagnosed with new coronary pneumonia. Remdesivir is one of the treatment drugs. Gilead also published research results saying that Remdesivir can shorten the recovery time of patients. However, a study released by the World Health Organization (WHO) on October 15 showed that remdesivir has little effect on the treatment of hospitalized patients with new coronary pneumonia. Remdesivir argued that the experimental data had not been strictly reviewed.
In May of this year, the FDA issued an emergency use authorization (EUA) for remdesivir to treat new coronary pneumonia, allowing hospitals to With the doctor the drug is used in hospitalized patients with new coronary pneumonia. As of now, RuiDesivir has been approved or authorized as a temporary treatment drug in about 50 countries and regions around the world.
In August, Gilead Sciences stated that the supply of Remdesivir has been more than 50 times the entire supply since January, and it is expected to meet global real-time demand from October. Gilead Sciences plans to produce more than 2 million courses of drugs by the end of this year, and is expected to produce several million courses of drugs in 2021.
Regardless of the global situation, the approval of Remdesivir is particularly important to the United States, where the number of confirmed cases is growing rapidly and the base is large. This also lays the foundation for the potentially huge revenue of Remdesivir.
According to Worldometer’s real-time statistics, as of about 6:30 on October 23, Beijing time, a total of 8,651,581 cases of new coronary pneumonia were confirmed in the United States and a total of 228,269 deaths. In the past week, the average number of newly confirmed cases in a single day in the United States was about 60,000. This figure was about 35,000 in mid-September.
According to the US Consumer News and Business Channel (CNBC), for patients covered by public health insurance or other countries’ health insurance programs, the cost of a 5-day course of treatment is US$2340; For patients with private medical insurance, the cost is US$3,120.
Piper Sandler analyst Tyler Van Buren believes that according to the current situation, Remdesivir will bring Gilead in sales of more than $1 billion in the second half of the year.
Scan the QR code to enter the group